Home » Stocks » GLYC

GlycoMimetics, Inc. (GLYC)

Stock Price: $3.81 USD 0.02 (0.53%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $3.83 +0.02 (0.53%) Jan 20, 7:48 PM
Market Cap 183.68M
Revenue (ttm) 10.00M
Net Income (ttm) -50.19M
Shares Out 47.51M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $3.81
Previous Close $3.79
Change ($) 0.02
Change (%) 0.53%
Day's Open 3.86
Day's Range 3.74 - 3.90
Day's Volume 510,489
52-Week Range 1.83 - 5.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition disclosed new data re...

Business Wire - 1 month ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics' (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown t...

Business Wire - 2 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Health...

Seeking Alpha - 2 months ago

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. ...

Business Wire - 2 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company's clinical and research portfolio have been accepted fo...

Business Wire - 2 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, Nov...

Business Wire - 2 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owne...

Seeking Alpha - 3 months ago

GlycoMimetics is undervalued based on its AML therapy potential.

Zacks Investment Research - 3 months ago

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

Business Wire - 3 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designatio...

Business Wire - 4 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

Business Wire - 4 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

Business Wire - 4 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

Seeking Alpha - 5 months ago

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

Business Wire - 5 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

Business Wire - 6 months ago

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on Jul...

Zacks Investment Research - 6 months ago

GlycoMimetics (GLYC) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

GlycoMimetics (GLYC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

GlycoMimetics' Focus Is On AML Therapy

Seeking Alpha - 1 year ago

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pharma sector wins in October, making these ETFs and stocks winners.

Other stocks mentioned: DERM, IRWD, PJP, PPH, RIGL, XPH
Seeking Alpha - 1 year ago

Biotech concern GlycoMimetics fell sharply in early August when its out-licensed candidate rivipansel flunked a Phase 3 trial.

Seeking Alpha - 1 year ago

Much of GlycoMimetics' value was supposed to be in the uproleselan AML therapy.

GuruFocus - 1 year ago

Falling Knives are companies whose share prices have fallen more than 59% over the past year, generating the interest of investors as they can make huge gains if they bounce back.

Other stocks mentioned: NCNA
Zacks Investment Research - 1 year ago

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

24/7 Wall Street - 1 year ago

GlycoMimetics Inc. (NASDAQ: GLYC) shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease (SCD) trial in conjunction with Pfizer Inc.

Market Watch - 1 year ago

Shares of GlycoMimetics Inc. GLYC, -1.30% fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partner...

Benzinga - 1 year ago

GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key second...

Seeking Alpha - 1 year ago

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

GlycoMimetics, Inc. (GLYC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Seeking Alpha - 1 year ago

GlycoMimetics has an outlicensed lead candidate targeting VOC in SCD patients.

Seeking Alpha - 1 year ago

Today, we look at an interesting small-cap developmental concern with a couple of compounds in late-stage development.

Seeking Alpha - 1 year ago

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

As an innovator of carbohydrate-based medicines, GlycoMimetics is powering an enriched therapeutic pipeline for various cancers and medical conditions.

About GLYC

GlycoMimetics, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phas... [Read more...]

Industry
Biotechnology
IPO Date
Jan 10, 2014
CEO
Rachel King
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
GLYC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GlycoMimetics stock is "Buy." The 12-month stock price forecast is 10.50, which is an increase of 175.59% from the latest price.

Price Target
$10.50
(175.59% upside)
Analyst Consensus: Buy